Inhibition of FAO in AML co-cultured with BM adipocytes: mechanisms of survival and chemosensitization to cytarabine
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2045-2322
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Inhibition of FAO in AML co-cultured with BM adipocytes: mechanisms of survival and chemosensitization to cytarabine ; volume:8 ; number:1 ; day:15 ; month:11 ; year:2018 ; pages:1-12 ; date:12.2018
Scientific reports ; 8, Heft 1 (15.11.2018), 1-12, 12.2018
- Urheber
-
Tabe, Yoko
Saitoh, Kaori
Yang, Haeun
Sekihara, Kazumasa
Yamatani, Kotoko
Ruvolo, Vivian
Taka, Hikari
Kaga, Naoko
Kikkawa, Mika
Arai, Hajime
Miida, Takashi
Andreeff, Michael
Spagnuolo, Paul A.
Konopleva, Marina
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1038/s41598-018-35198-6
- URN
-
urn:nbn:de:101:1-2018122723165284179981
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:54 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Tabe, Yoko
- Saitoh, Kaori
- Yang, Haeun
- Sekihara, Kazumasa
- Yamatani, Kotoko
- Ruvolo, Vivian
- Taka, Hikari
- Kaga, Naoko
- Kikkawa, Mika
- Arai, Hajime
- Miida, Takashi
- Andreeff, Michael
- Spagnuolo, Paul A.
- Konopleva, Marina
- SpringerLink (Online service)
Ähnliche Objekte (12)
Novel formulation of cytarabine and daunorubicin: A new hope in AML treatment
![Genome-wide CRISPR/Cas9 combined cytarabine resistance and sensitizer screen in AML cell lines, [Band].](/assets/placeholder/searchResultMediaNoDigitisedMedia.png)
Genome-wide CRISPR/Cas9 combined cytarabine resistance and sensitizer screen in AML cell lines, [Band].
Medium-cumulative dose of cytarabine in consolidation therapy shows the greatest benefit in AML patients
Manipulation of SAMHD1 using lentiviral protein Vpx to increase sensitivity of AML cells to cytarabine
Adjunction of a fish oil emulsion to cytarabine and daunorubicin induction chemotherapy in high-risk AML
Disrupting the LC3 interaction region (LIR) binding of selective autophagy receptors sensitizes AML cell lines to cytarabine
Intensified cytarabine dose during consolidation in adult AML patients under 65 years is not associated with survival benefit: real-world data from the German SAL-AML registry
Intensified cytarabine dose during consolidation in adult AML patients under 65 years is not associated with survival benefit: real-world data from the German SAL-AML registry
Intensified cytarabine dose during consolidation in adult AML patients under 65 years is not associated with survival benefit: real-world data from the German SAL-AML registry
Successful fat-only whole breast reconstruction using cultured mature adipocytes and conditioned medium containing MCP-1
EIF4A inhibition targets bioenergetic homeostasis in AML MOLM-14 cells in vitro and in vivo and synergizes with cytarabine and venetoclax
Cytarabine-induced differentiation of AML cells depends on Chk1 activation and shares the mechanism with inhibitors of DHODH and pyrimidine synthesis
Novel formulation of cytarabine and daunorubicin: A new hope in AML treatment
Genome-wide CRISPR/Cas9 combined cytarabine resistance and sensitizer screen in AML cell lines, [Band].
Medium-cumulative dose of cytarabine in consolidation therapy shows the greatest benefit in AML patients
Manipulation of SAMHD1 using lentiviral protein Vpx to increase sensitivity of AML cells to cytarabine
Adjunction of a fish oil emulsion to cytarabine and daunorubicin induction chemotherapy in high-risk AML
Disrupting the LC3 interaction region (LIR) binding of selective autophagy receptors sensitizes AML cell lines to cytarabine
Intensified cytarabine dose during consolidation in adult AML patients under 65 years is not associated with survival benefit: real-world data from the German SAL-AML registry
Intensified cytarabine dose during consolidation in adult AML patients under 65 years is not associated with survival benefit: real-world data from the German SAL-AML registry
Intensified cytarabine dose during consolidation in adult AML patients under 65 years is not associated with survival benefit: real-world data from the German SAL-AML registry
Successful fat-only whole breast reconstruction using cultured mature adipocytes and conditioned medium containing MCP-1
EIF4A inhibition targets bioenergetic homeostasis in AML MOLM-14 cells in vitro and in vivo and synergizes with cytarabine and venetoclax
Cytarabine-induced differentiation of AML cells depends on Chk1 activation and shares the mechanism with inhibitors of DHODH and pyrimidine synthesis
Novel formulation of cytarabine and daunorubicin: A new hope in AML treatment
Genome-wide CRISPR/Cas9 combined cytarabine resistance and sensitizer screen in AML cell lines, [Band].
Medium-cumulative dose of cytarabine in consolidation therapy shows the greatest benefit in AML patients
Manipulation of SAMHD1 using lentiviral protein Vpx to increase sensitivity of AML cells to cytarabine
Adjunction of a fish oil emulsion to cytarabine and daunorubicin induction chemotherapy in high-risk AML
Disrupting the LC3 interaction region (LIR) binding of selective autophagy receptors sensitizes AML cell lines to cytarabine
Intensified cytarabine dose during consolidation in adult AML patients under 65 years is not associated with survival benefit: real-world data from the German SAL-AML registry
Intensified cytarabine dose during consolidation in adult AML patients under 65 years is not associated with survival benefit: real-world data from the German SAL-AML registry
Intensified cytarabine dose during consolidation in adult AML patients under 65 years is not associated with survival benefit: real-world data from the German SAL-AML registry
Successful fat-only whole breast reconstruction using cultured mature adipocytes and conditioned medium containing MCP-1
EIF4A inhibition targets bioenergetic homeostasis in AML MOLM-14 cells in vitro and in vivo and synergizes with cytarabine and venetoclax